Chaowei Zhang , Meirong Zhao , Dongyu Huang , Yubin Lei , Jie Ma , Xiaojian Li , Yan Wu , Zhendan He , Yifu Guan , Hedong Bian , Xun Song
{"title":"一种新的芳基萘木脂素类似物靶向CYP51抑制新型隐球菌的生长","authors":"Chaowei Zhang , Meirong Zhao , Dongyu Huang , Yubin Lei , Jie Ma , Xiaojian Li , Yan Wu , Zhendan He , Yifu Guan , Hedong Bian , Xun Song","doi":"10.1016/j.bioorg.2025.108900","DOIUrl":null,"url":null,"abstract":"<div><div>JR20, a novel arylnaphthalene lignan derivative, exhibits potent antifungal activity against <em>Cryptococcus neoformans</em> (IC<sub>50</sub> = 2.82 μg/mL) through dual mechanisms targeting CYP51 and mitochondrial function. Mechanistic studies combining molecular docking, transcriptomics, and biochemical assays confirmed JR20's specific binding to CYP51, significantly reducing ergosterol biosynthesis and causing membrane disruption (evidenced by SEM/TEM showing cell wall collapse and plasmolysis). Flow cytometry revealed fungal necrosis induction, while mitochondrial dysfunction was demonstrated through membrane potential loss, ROS accumulation, and ATP synthesis impairment. <em>In vivo</em> studies using a murine deep infection model demonstrated JR20's therapeutic efficacy, showing both anti-infective and anti-inflammatory properties. As a lignan derivative, JR20 represents a promising antifungal candidate addressing drug resistance through its unique dual-action mechanism, highlighting the potential of natural product research for developing novel antifungals against resistant pathogens.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"165 ","pages":"Article 108900"},"PeriodicalIF":4.7000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A novel arylnaphthalene lignan analogue targets CYP51 to inhibit Cryptococcus neoformans growth\",\"authors\":\"Chaowei Zhang , Meirong Zhao , Dongyu Huang , Yubin Lei , Jie Ma , Xiaojian Li , Yan Wu , Zhendan He , Yifu Guan , Hedong Bian , Xun Song\",\"doi\":\"10.1016/j.bioorg.2025.108900\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>JR20, a novel arylnaphthalene lignan derivative, exhibits potent antifungal activity against <em>Cryptococcus neoformans</em> (IC<sub>50</sub> = 2.82 μg/mL) through dual mechanisms targeting CYP51 and mitochondrial function. Mechanistic studies combining molecular docking, transcriptomics, and biochemical assays confirmed JR20's specific binding to CYP51, significantly reducing ergosterol biosynthesis and causing membrane disruption (evidenced by SEM/TEM showing cell wall collapse and plasmolysis). Flow cytometry revealed fungal necrosis induction, while mitochondrial dysfunction was demonstrated through membrane potential loss, ROS accumulation, and ATP synthesis impairment. <em>In vivo</em> studies using a murine deep infection model demonstrated JR20's therapeutic efficacy, showing both anti-infective and anti-inflammatory properties. As a lignan derivative, JR20 represents a promising antifungal candidate addressing drug resistance through its unique dual-action mechanism, highlighting the potential of natural product research for developing novel antifungals against resistant pathogens.</div></div>\",\"PeriodicalId\":257,\"journal\":{\"name\":\"Bioorganic Chemistry\",\"volume\":\"165 \",\"pages\":\"Article 108900\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioorganic Chemistry\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0045206825007801\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic Chemistry","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0045206825007801","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
A novel arylnaphthalene lignan analogue targets CYP51 to inhibit Cryptococcus neoformans growth
JR20, a novel arylnaphthalene lignan derivative, exhibits potent antifungal activity against Cryptococcus neoformans (IC50 = 2.82 μg/mL) through dual mechanisms targeting CYP51 and mitochondrial function. Mechanistic studies combining molecular docking, transcriptomics, and biochemical assays confirmed JR20's specific binding to CYP51, significantly reducing ergosterol biosynthesis and causing membrane disruption (evidenced by SEM/TEM showing cell wall collapse and plasmolysis). Flow cytometry revealed fungal necrosis induction, while mitochondrial dysfunction was demonstrated through membrane potential loss, ROS accumulation, and ATP synthesis impairment. In vivo studies using a murine deep infection model demonstrated JR20's therapeutic efficacy, showing both anti-infective and anti-inflammatory properties. As a lignan derivative, JR20 represents a promising antifungal candidate addressing drug resistance through its unique dual-action mechanism, highlighting the potential of natural product research for developing novel antifungals against resistant pathogens.
期刊介绍:
Bioorganic Chemistry publishes research that addresses biological questions at the molecular level, using organic chemistry and principles of physical organic chemistry. The scope of the journal covers a range of topics at the organic chemistry-biology interface, including: enzyme catalysis, biotransformation and enzyme inhibition; nucleic acids chemistry; medicinal chemistry; natural product chemistry, natural product synthesis and natural product biosynthesis; antimicrobial agents; lipid and peptide chemistry; biophysical chemistry; biological probes; bio-orthogonal chemistry and biomimetic chemistry.
For manuscripts dealing with synthetic bioactive compounds, the Journal requires that the molecular target of the compounds described must be known, and must be demonstrated experimentally in the manuscript. For studies involving natural products, if the molecular target is unknown, some data beyond simple cell-based toxicity studies to provide insight into the mechanism of action is required. Studies supported by molecular docking are welcome, but must be supported by experimental data. The Journal does not consider manuscripts that are purely theoretical or computational in nature.
The Journal publishes regular articles, short communications and reviews. Reviews are normally invited by Editors or Editorial Board members. Authors of unsolicited reviews should first contact an Editor or Editorial Board member to determine whether the proposed article is within the scope of the Journal.